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 CURRENTOPINION Optical coherence tomography as a means to
characterize visual pathway involvement in
multiple sclerosis
Carla A. Wickia,b, James V.M. Hansonb,c, and Sven Schipplingb
Purpose of review
Optical coherence tomography (OCT) is a noninvasive in-vivo imaging tool that enables the quantification
of the various retinal layer thicknesses. Given the frequent involvement of the visual pathway in multiple
sclerosis, OCT has become an important tool in clinical practice, research and clinical trials. In this review,
the role of OCT as a means to investigate visual pathway damage in multiple sclerosis is discussed.
Recent findings
Evidence from recent OCT studies suggests that the peripapillary retinal nerve fibre layer (pRNFL) appears
to be an ideal marker of axonal integrity, whereas the macular ganglion cell and inner plexiform layer
(GCIP) thickness enables early detection of neuronal degeneration in multiple sclerosis. The thickness of the
macular inner nuclear layer (INL) has been suggested as a biomarker for inflammatory disease activity and
treatment response in multiple sclerosis. OCT parameters may also be used as an outcome measure in
clinical trials evaluating the neuroprotective or regenerative potential of new treatments.
Summary
OCT provides insights into multiple sclerosis beyond the visual pathway. It is capable of quantifying the
major pathological hallmarks of the disease, specifically inflammation and neuroaxonal degeneration.
OCT, therefore, has the potential to become another mainstay in the monitoring of multiple sclerosis
patients.
Keywords
afferent visual pathway, low-contrast visual acuity, multiple sclerosis, optic neuritis, optical coherence
tomography
INTRODUCTION
Multiple sclerosis is the most common chronic
inflammatory demyelinating disorder of the central
nervous system (CNS) and the main cause of non-
traumatic neurological disability in young adults
[1]. Inflammation, demyelination and neurodegen-
eration are key pathological features of multiple
sclerosis [2]. Neuroaxonal damage occurs even in
the earliest stages of the disease, as demonstrated in
clinically isolated syndrome (CIS), and is responsi-
ble for persistent neurological disability [3–6].
Despite a heterogeneous clinical presentation,
impaired vision is a frequent symptom and among
the most common early manifestations of the dis-
ease [7,8], with 21% of CIS patients presenting with
optic neuritis [7]. Optic neuritis represents the most
frequent involvement of the afferent visual pathway
(AVP) in multiple sclerosis, causing neuroaxonal
damage of the optic nerves and retina leading to
chronic functional impairment [9]. A recent study
showed that visual function is rated by multiple
sclerosis patients as their most important bodily
function, independently of disease duration or dis-
ability [10]. However, involvement of the optic
nerve even in the absence of a clinical history of
optic neuritis has frequently been found in multiple
sclerosis [11–13]. The AVP has been proposed as an
ideal model to study both neurodegeneration and
repair inmultiple sclerosis, because of its retinotopic
aDepartment of Health Science and Technology, Swiss Federal Institute
of Technology, bNeuroimmunology and Multiple Sclerosis Research,
Department of Neurology and cDepartment of Ophthalmology, University
Hospital Zurich and University of Zurich, Zurich, Switzerland
Correspondence to Sven Schippling, Department of Neurology, Univer-
sity Hospital Zurich and University of Zurich, Frauenklinikstrasse 26, CH-
8091 Zurich, Switzerland. Tel: +41 44 255 12 18;
e-mail: Sven.Schippling@usz.ch
Curr Opin Neurol 2018, 31:000–000
DOI:10.1097/WCO.0000000000000604
1350-7540 Copyright  2018 Wolters Kluwer Health, Inc. All rights reserved. www.co-neurology.com
REVIEW
Copyright © 2018 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
CE: Alpana; WCO/310510; Total nos of Pages: 7;
WCO 310510
organization throughout (ensuring that anatomical
structure is linked to corresponding visual function)
and anatomical discreteness [14]. Optical coherence
tomography (OCT) permits the assessment and
quantification of the retinal layers by generating a
high-resolution cross-sectional view of the retina
[15]. The use of OCT in both research and clinical
practice, plays an important role in monitoring the
integrity of the retinal architecture, and also in
gaining a better understanding of the process of
neuronal degeneration following optic neuritis.
OPTICAL COHERENCE TOMOGRAPHY
OCT generates tomographic, two-dimensional
in-vivo images of the retina using low-coherent,
near-infrared light. It is rapid, noninvasive, well
tolerated, cost-effective and reproducible [15,16].
Contemporary spectral-domain OCT (SD-OCT)
technology allows the visualization of the neural
retina with an axial resolution in the range of
3–6mm [17,18]. Two of the most common scan
protocols are the optic nerve head (ONH) and mac-
ular volume scans. The ONH scan (also described as
the peripapillary ring scan) generates circular two-
dimensional B-scans centred on the optic disc. This
protocol facilitates measurement of the thickness of
the peripapillary retinal nerve fibre layer (pRNFL)
around the ONH [19,20]. Scan quality control
should be performed, for example, according to
the OSCAR-IB consensus criteria [21,22]. As the
pRNFL contains unmyelinated axons of the retinal
ganglion cells (RGCs), a thickness reduction most
likely reflects axonal thinning or loss rather than
loss of myelin, rendering the pRNFL an ideal marker
of axonal damage [23,24
&
]. The macular volume
scan consists of two-dimensional B-scans centred
over the fovea from which a three-dimensional
image of the central retina is extrapolated. For post-
processing, the macula is divided into sectors
according to the ETDRS (Early Treatment of Diabetic
Retinopathy Study) grid [25]. Current SD-OCT devi-
ces typically ship with proprietary software, which
delineates the borders of the retinal layers (a process
known as ‘automated segmentation’) and calculates
the thicknesses and volumes of the individual reti-
nal layers (Fig. 1). Manual verification and, if neces-
sary, correction of the automated segmentation is
recommended in order to ensure accuracy [26]. As
the boundary between the macular ganglion cell
layer (GCL) and inner plexiform layer (IPL) is diffi-
cult to accurately distinguish, the two layers are
often combined for analysis as themacular ganglion
cell and inner plexiform layer (GCIP). pRNFL, total
macular volume (TMV), and, more recently, GCIP
and the inner nuclear layer (INL) appear to be the
most widely studied retinal layers in multiple scle-
rosis research. Reductions in GCIP thickness are
assumed to reflect primarily thinning of the GCL
and, thus, atrophy of the cell bodies of the RGCs;
GCIP thickness is, therefore, used as a biomarker for
neurodegeneration within the retina [24
&
,27]. The
INL consists of the amacrine, bipolar and horizontal
cells as well as the cell bodies of the M€uller cells, the
most abundant glial cell of the retina [28]. In recent
years, researchers have proposed the INL as a bio-
marker for inflammation in multiple sclerosis
[24
&
,29
&&
]. Together, the peripapillary ring scan
and the macular volume scan permit a comprehen-
sive overview of the retina and retinal disease [30].
In recent years, crucial efforts were made to provide
standardized acquisition protocols, guidance for
quality control and recommendations for reporting,
resulting in a substantial improvement of research
[21,22,31].
CHARACTERIZING VISUAL
PATHWAYWAY INVOLVEMENT WITH
OPTICAL COHERENCE TOMOGRAPHY
Pathological OCT findings may be because of vari-
ous underlying aetiologies. The following section
summarizes the most important pathological OCT
findings associated with multiple sclerosis.
Optic neuritis
Acute optic neuritis is an inflammatory, demyelin-
ating event affecting the optic nerve, and is fre-
quently associated with multiple sclerosis [8].
KEY POINTS
 In recent years, OCT has become an important tool in
both multiple sclerosis research and multiple sclerosis
clinical practice.
 OCT enables the quantification of neuroaxonal
damage and inflammatory disease activity within the
retina of multiple sclerosis patients.
 Multiple sclerosis patients develop significant inner
retinal atrophy during their disease course, regardless
of whether they experience an episode of optic neuritis.
 OCT measurements show that neuroaxonal retinal
damage develops rapidly in multiple sclerosis and
correlates negatively with visual performance, disability
and quality of life.
 Retinal OCT can assist in clinical multiple sclerosis
management, specifically with diagnosis, monitoring
and prognosis of individual multiple sclerosis patients.
Special commentary
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Twenty to 25% of all multiple sclerosis patients
manifest with acute optic neuritis as their clinical
index event, whereas up to 70% of patients are
affected at some point during their disease course
[8,32]. Acute onset of unilateral retrobulbar pain
upon eye movement, reduced vision, colour desatu-
ration and visual field defects are typical symptoms
suggestive of optic neuritis [33]. Symptoms worsen
over days or weeks, followed by partial recovery over
a period of months. A recent study suggests that
patients are frequently left with persistent visual
impairment, in particular, affecting low-contrast
visual acuity (LCVA), colour vision and visual qual-
ity of life [National Eye Institute Visual Function
Questionnaire-25 (NEI-VFQ-25)] [34
&&
]. The patho-
physiology of acute optic nerve lesions resembles
that of multiple sclerosis brain lesions, where
inflammatory demyelination is predominantly
mediated by autoreactive T cells, with involvement
from B cells, microglia and antibodies [35]. In
approximately one-third of optic neuritis patients,
acute inflammation is also present in the retina
around the ONH, as evidenced by an initial increase
in pRNFL thickness, most likely reflecting inflam-
matory oedema [36]. Resolution of this oedema over
time may mask concurrent pRNFL thinning. The
currentmechanistic understanding is that alongside
inflammatory demyelination, the optic nerve suf-
fers from axonal damage. This results in retrograde
degeneration from the retrobulbar optic nerve
towards the ganglion cell bodies of the retina [37].
Using OCT, retrograde degeneration can be visual-
ized in a reduction of pRNFL and GCIP thickness
[23,27]. Two important prospective longitudinal
studies found a progressive decline of pRNFL thick-
ness over 12 months following optic neuritis, with
most of the reduction occurring within the first
3 months post-onset [38,39]. Similar results were
found for the macular GCIP thickness [39]. Impor-
tantly, as opposed to pRNFL, measures of macular
GCIP are usually uncontaminated by inflammatory
oedema and degeneration of retinal neurons is
detectable as early as 1 month after optic neuritis
onset [39]. The rate of atrophy becomes lower with
FIGURE 1. Optical coherence tomography-derived macular ganglion cell layer thickness (mm) for the right eye of a multiple
sclerosis patient. Left: for postprocessing the macula is divided into sectors according to the ETDRS grid. Right: shown is a
typical case of macular GCL atrophy following an episode of optic neuritis: Baseline macular GCL thickness is in a normal
range at clinical presentation of optic neuritis, displayed on the thickness map by the yellowish colour, but shows an apparent
decrease in its thickness at the 12-month follow-up examination, illustrated by the dark reddish colour. The bottom image
shows the change of GCL thickness between the two examination timepoints. ETDRS, Early Treatment of Diabetic Retinopathy
Study; GCL, ganglion cell layer; OCT, optical coherence tomography.
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longer disease duration, suggestive of a plateau
effect [40]. Optic neuritis also appears to affect outer
retinal layers, namely the INL, outer plexiform layer
(OPL), outer nuclear layer (ONL) and photoreceptor
complex, suggesting trans-synaptic alterations [41].
These outer retinal layers exhibit thickening rather
than thinning, which may indicate outer retinal
inflammation [41].
Although optic neuritis is frequently associated
with multiple sclerosis, there are many other possi-
ble causes of optic neuritis. Among the various
differential diagnoses, neuromyelitis optica spec-
trum disorder (NMOSD) and myelin oligodendro-
cyte glycoprotein (MOG)-antibody-associated optic
neuritis are of particular importance [42]. Signs
suggestive of atypical non multiple sclerosis-related
optic neuritis include painless or very painful onset,
simultaneous bilateral involvement, severe or com-
plete visual loss with poor recovery, or haemor-
rhages and exudates detectable on fundoscopy [42].
Microcystic macular oedema
Microcysticmacular oedema (MME) can be observed
in around 5% of patients withmultiple sclerosis and
present as discrete, cyst-like spaces restricted to the
INL [43,44]. Various causes have been proposed,
including a disruption of the blood–retinal barrier
[44]. The prevalence of MME is higher in eyes with,
but can also be found in eyes without, a history of
optic neuritis [43].
Primary retinal pathology
Saidha et al. [45] described a subset of multiple
sclerosis patients with a novel OCT-defined pheno-
type characterized by normal pRNFL thickness but
reduced macular thickness (with disproportionate
thinning of the INL and ONL) when compared with
other multiple sclerosis patients and healthy con-
trols, unattributable to retrograde degeneration, and
interpreted as evidencing primary retinal disease.
Using electroretinography (ERG) and OCT, we
recently showed evidence of bipolar cell and pho-
toreceptor dysfunction (located in the INL andONL,
respectively) in the absence of corresponding struc-
tural changes and independent of optic neuritis
[46
&
]. The ERG findings are corroborated by You
et al. [47] in a cohort without previous optic neuritis.
Together, these findings support the idea of primary
retinal abnormalities in multiple sclerosis patients.
Posterior visual pathway pathology
In multiple sclerosis patients without prior optic
neuritis, pRNFL thinning is associated with atrophy
of the optic radiations and primary visual cortex as
assessed by MRI. Authors have interpreted that
lesions in the posterior visual pathway may result
in a thinning of the pRNFL by trans-synaptic (via the
lateral geniculate nucleus of the thalamus) retro-
grade axonal degeneration, however, this needs to
be verified by more mechanistic studies [48–50]. In
eyes without prior optic neuritis, it has been pro-
posed that posterior visual pathway pathology
accounts for as much as 35–40% of pRNFL thinning
[50,51]. Conversely, optic nerve disease may also
result in trans-synaptic anterograde degeneration,
affecting parts of the posterior visual pathway, as
indicated by more severe visual cortex atrophy in
multiple sclerosis patients with a previous history of
optic neuritis [48,52].
CLINICAL RELEVANCE OF OPTICAL
COHERENCE TOMOGRAPHY FINDINGS IN
MULTIPLE SCLEROSIS
In order to validate the utility of OCT as a clinical and
research tool in multiple sclerosis, the functional rele-
vanceandimplicationsof thestructural retinalchanges
discussed above is of critical importance. There is a
significant body of evidence showing that OCT out-
comes are associated with both visual and overall dis-
ability, disease activity, and, increasingly, response to
treatment in multiple sclerosis [29
&&
,53,54].
Firstly, measures of visual performance includ-
ing visual acuity, colour vision and perimetry have
been shown to correlate with the thicknesses of the
pRNFL and evenmore strongly with the thickness of
the macular GCIP [53,55–58]. In particular, LCVA
has been shown to strongly correlate with OCT
outcomes, and is probably the most sensitive mea-
sure to capture visual dysfunction following optic
neuritis [59
&
]. The importance of LCVA monitoring
becomes obvious when considering the higher prev-
alence of residual low contrast as opposed to high-
contrast visual functional impairment following
optic neuritis [59
&
]. Moreover, a study with optic
neuritis patients demonstrated that the GCIP and
pRNFL thickness changes within the first month
following optic neuritis onset could predict visual
recovery, measured by LCVA and colour vision, at
month 6 [34
&&
]. Visual recovery after optic neuritis
tends to be better in women thanmen andmay also
be associated with serum vitamin D levels [38,60].
A significant relationship between OCT para-
meters and electrophysiological tests such as the
visual evoked potential (VEP) and ERG has been
observed in multiple sclerosis [61]. VEP and ERG
examinations are performed in order to quantify the
cortical (VEP) and retinal (ERG) response to precisely
defined visual stimuli [62].
Special commentary
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The Expanded Disability Status Scale (EDSS),
widely used to assess multiple sclerosis-related dis-
ability, is weighted towards motor impairment and
problems with gait, whereas visual functional defi-
cits are highly underrepresented [63]. Despite this,
studies of multiple sclerosis patients without previ-
ous optic neuritis have found that a pRNFL thickness
value below a certain threshold (varying by OCT
device), measured at any given timepoint in the
disease, was predictive of a more severe disability
progression (as measured by EDSS) relative to those
patients with greater pRNFL thickness [54]. Further,
a strong relationship between cognitive impairment
and atrophy of the pRNFL and macular GCIP has
been found [64]. Additionally, a reduction in quality
of life is associated with a reduction in the thickness
of the pRNFL [65].
Likewise, the presence of MME has been associ-
ated with disease severity in multiple sclerosis
patients [43,44]. It has been suggested that an
increase in INL thickness, with or without visible
MME, may be reflective of inflammatory disease
activity in multiple sclerosis [44]. Patients with
relapsing–remitting multiple sclerosis, who had
relapses or new gadolinium-enhancing lesions dur-
inga3-year follow-upperiod,hadhigherbaseline INL
thicknesses compared with patients who did not
have relapses [44]. Knier et al. [29
&&
] recently reported
that INL thickness was greater in untreated multiple
sclerosis patients than healthy controls, and that
patients responding to immune therapies show a
normalization of INL thickness, indicating a reduc-
tion in inflammatory disease activity. As a result, the
INL has gained significant interest as a possible bio-
marker for treatment response [29
&&
]. Subsequent
findings from the same centre show an association
between INL volume and prospective MRI activity
(T2 lesion load and number of gadolinium-enhanc-
ing lesions) [66
&
], providing further evidence for the
emerging importanceof the INL inmultiple sclerosis.
In addition, several studies have shown that
injury in the AVP reflects global CNS damage in
multiple sclerosis that can be quantified using
MRI [67–69]. Currently, MRI is the mainstay of
diagnosis and monitoring of multiple sclerosis
and the most accepted surrogate marker of disease
progression. pRNFL thinning has been shown to be
associated with whole-brain atrophy [67,68]. Fur-
thermore, Saidha and colleagues have found that
GCIP atrophy reflects greymatter atrophy over time,
an important measure of disease progression [69–
71]. However, MRI is expensive and time-consum-
ing. As a sensitive, accurate, rapid and cost-effective
tool, OCT provides an excellent complement to
MRI for monitoring CNS integrity in patients with
multiple sclerosis.
Consequent to the remarkable development of
OCT technology over recent years, particularly with
regard to retinal layer segmentation, OCT may be
helpful in the characterization of pathologically
distinct multiple sclerosis phenotypes. For example,
patients exhibiting primary retinal pathology have
been proposed to have an aggressive form of multi-
ple sclerosis, characterized by more rapid disability
progression [45], as have patients with MME [43].
Consideration of disease phenotype, stage, activity
and progression of individual patients is important
for optimal disease management and OCT will
increasingly play a vital role in the assessment
and management of these patients.
Inner retinal layer (RNFL; GCIP) changes are
already detectable in CIS patients not yet diagnosed
with multiple sclerosis but presenting with a first
clinical event suggestive of multiple sclerosis [6].
Hence, OCT may potentially aid the early detection
of at-risk patients and facilitate early diagnosis of
multiple sclerosis. As irreversible axonal and neuro-
nal injury can occur even in the earliest stages of
multiple sclerosis, early detection and treatment is a
high priority [72].
Moreover, differential diagnosis is of great
importance; for instance, the prognosis and treat-
ment of optic neuritis depends strongly on the
underlying cause [8]. Optic neuritis associated with
AQP4-seropositivity has been associated with a
more severe clinical outcome, as have some (but
not all) cases of MOG-seropositive optic neuritis
[73]. Early diagnosis and appropriate treatment
are paramount to avoid severe functional sequelae,
including blindness, which further emphasizes the
utility of OCT in patients with acute optic neuritis
[74–76].
During recent years, OCT measures have been
proven as appropriate outcome measures in multi-
ple sclerosis clinical trials, often in combination
with LCVA and other clinical measures [77]. In
particular, optic neuritis has been proposed as a
unique clinical model to study the potential of
neuroprotective and neurodegenerative therapies.
The thickness of the pRNFL may serve as a robust
long-term axonal outcome measure, whilst the
thickness of themacular GCIP is considered an early
measure of neuronal integrity [24
&
,78
&
,79]. Results
from recent longitudinal OCT studies focusing on
the timing of neuroaxonal loss in multiple sclerosis
may have important implications for future clinical
trial planning, in particular, with regards to the
timing of treatment intervention. As atrophy is
most pronounced at early stages of the disease
course, early or even hyperacute intervention may
be the most promising strategy to prevent irrevers-
ible neuroaxonal degeneration [40,78
&
].
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CONCLUSION
OCT has been validated as a reliable tool for quanti-
fying the major pathological hallmarks of multiple
sclerosis disease: inflammation, axonal loss and
neuronal degeneration [8,24
&
,28,80]. OCT has the
potential to become amainstay in themonitoring of
multiple sclerosis patients as it may provide impor-
tant complementary information to MRI, thereby
assisting in the clinical decision-making process.
OCT may also be used as an outcome measure in
clinical trials of new compounds with neuroprotec-
tive and neuroregenerative potential.
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